Hyam Levitsky, M.D.
Roche Glycart AG, Schlieren, Switzerland,
and The Johns Hopkins University School of Medicine, Baltimore, MD
Dr. Hyam Levitsky is head of cancer immunology experimental medicine at Roche and professor of oncology, medicine & urology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Levitsky's laboratory research has focused on basic studies of antigen processing and presentation, T cell co-stimulation, T cell priming versus tolerance, and the evolution of tumor-specific immunity during immune reconstitution. He is a co-inventor of genetically modified GM-CSF secreting tumor cell vaccines (GVAX), now in phase III clinical trials for treatment of prostate cancer, and phase II trials for acute and chronic myeloid leukemia, multiple myeloma, and pancreas cancer. At Johns Hopkins, Dr. Levitsky is the scientific director of the George Santos Bone Marrow Transplant Program, and has been a pioneer in the integration of therapeutic cancer vaccines during immune reconstitution following high dose chemotherapy and stem cell transplantation.
Dr. Levitsky has served on the Board of Directors of Antigenics since 2006, and is currently on the Scientific Advisory Boards of Celldex, Dendreon, and Johnson & Johnson. Dr. Levitsky has received numerous awards for his research, including the Stohlman Scholars Award from the Leukemia and Lymphoma Foundation of America, The Senior Research Award from the Multiple Myeloma Research Foundation, Research Awards from the CapCURE Foundation, the American Cancer Society, and the National Institutes of Health. In 2001, he was elected to the American Society for Clinical Investigation. Dr. Levitsky received his undergraduate education at the University of Pennsylvania, and his medical degree at the Johns Hopkins University School of Medicine.